Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Pandion Therapeutics, Inc. (PAND)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-20Sep-30-20Jun-30-20Mar-31-20Dec-31-19
   10-K10-Q10-QS-1/A10-K
Revenue  7.75.62.91.08.4
            Revenue growth  -7.7%    
Operating expenses       
Research and development  27.021.917.0 13.1
General and administrative  16.213.510.79.26.9
    Total operating expenses  61.453.645.940.528.4
    Loss from operations  -53.6-47.1-42.0-38.6-27.4
            Operating margin  -692.6%-847.8%-1437.6%-3989.6%-326.8%
Interest income  0.30.30.40.50.4
Interest expense  -0.3-0.3-0.10.0 
    Net loss  -53.6-46.9-41.5-38.0-27.0
Change in redemption value of redeemable convertible preferred shares   -4.4-4.8 -3.0
    Net loss attributable to common shares – basic and diluted  -35.1-29.4-24.4-19.1-19.1
   
Net loss per common share, basic and diluted  ($35.12)($40.75)($46.96)($43.11)($35.11)
   
Weighted-average number of shares used in computing net loss per common share, basic and diluted  9.56.40.80.80.8

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy